378 related articles for article (PubMed ID: 22493262)
1. Aristolochic acid-associated urothelial cancer in Taiwan.
Chen CH; Dickman KG; Moriya M; Zavadil J; Sidorenko VS; Edwards KL; Gnatenko DV; Wu L; Turesky RJ; Wu XR; Pu YS; Grollman AP
Proc Natl Acad Sci U S A; 2012 May; 109(21):8241-6. PubMed ID: 22493262
[TBL] [Abstract][Full Text] [Related]
2. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes.
Chen CH; Dickman KG; Huang CY; Moriya M; Shun CT; Tai HC; Huang KH; Wang SM; Lee YJ; Grollman AP; Pu YS
Int J Cancer; 2013 Jul; 133(1):14-20. PubMed ID: 23292929
[TBL] [Abstract][Full Text] [Related]
3. Aristolochic acid-containing Chinese herbal medicine and upper urinary tract urothelial carcinoma in Taiwan: a narrative review.
Dickman KG; Chen CH; Grollman AP; Pu YS
World J Urol; 2023 Apr; 41(4):899-907. PubMed ID: 35867141
[TBL] [Abstract][Full Text] [Related]
4. TP53 Mutational signature for aristolochic acid: an environmental carcinogen.
Moriya M; Slade N; Brdar B; Medverec Z; Tomic K; Jelaković B; Wu L; Truong S; Fernandes A; Grollman AP
Int J Cancer; 2011 Sep; 129(6):1532-6. PubMed ID: 21413016
[TBL] [Abstract][Full Text] [Related]
5. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid.
Jelaković B; Karanović S; Vuković-Lela I; Miller F; Edwards KL; Nikolić J; Tomić K; Slade N; Brdar B; Turesky RJ; Stipančić Ž; Dittrich D; Grollman AP; Dickman KG
Kidney Int; 2012 Mar; 81(6):559-67. PubMed ID: 22071594
[TBL] [Abstract][Full Text] [Related]
6. Balkan Endemic Nephropathy and the Causative Role of Aristolochic Acid.
Jelaković B; Dika Ž; Arlt VM; Stiborova M; Pavlović NM; Nikolić J; Colet JM; Vanherweghem JL; Nortier JL
Semin Nephrol; 2019 May; 39(3):284-296. PubMed ID: 31054628
[TBL] [Abstract][Full Text] [Related]
7. Tumor suppressor p53 (TP53) at the crossroads of the exposome and the cancer genome.
Schetter AJ; Harris CC
Proc Natl Acad Sci U S A; 2012 May; 109(21):7955-6. PubMed ID: 22592801
[No Abstract] [Full Text] [Related]
8. Aristolochic Acid in the Etiology of Renal Cell Carcinoma.
Hoang ML; Chen CH; Chen PC; Roberts NJ; Dickman KG; Yun BH; Turesky RJ; Pu YS; Vogelstein B; Papadopoulos N; Grollman AP; Kinzler KW; Rosenquist TA
Cancer Epidemiol Biomarkers Prev; 2016 Dec; 25(12):1600-1608. PubMed ID: 27555084
[TBL] [Abstract][Full Text] [Related]
9. Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid.
Hollstein M; Moriya M; Grollman AP; Olivier M
Mutat Res; 2013; 753(1):41-49. PubMed ID: 23422071
[TBL] [Abstract][Full Text] [Related]
10. Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease.
Grollman AP
Environ Mol Mutagen; 2013 Jan; 54(1):1-7. PubMed ID: 23238808
[TBL] [Abstract][Full Text] [Related]
11. Evidence of exposure to aristolochic acid in patients with urothelial cancer from a Balkan endemic nephropathy region of Romania.
Schmeiser HH; Kucab JE; Arlt VM; Phillips DH; Hollstein M; Gluhovschi G; Gluhovschi C; Modilca M; Daminescu L; Petrica L; Velciov S
Environ Mol Mutagen; 2012 Oct; 53(8):636-41. PubMed ID: 22987305
[TBL] [Abstract][Full Text] [Related]
12. Variation in presentation and presence of DNA adducts and p53 mutations in patients with endemic nephropathy--an environmental form of the aristolochic acid nephropathy.
Karanović S; Lela IV; Jelaković B; Dickman KG; Peić AK; Dittrich D; Knežević M; Matijević V; Fernandes AS; Miller F
Kidney Blood Press Res; 2013; 37(1):1-8. PubMed ID: 23445829
[TBL] [Abstract][Full Text] [Related]
13. Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy.
Schmeiser HH; Nortier JL; Singh R; Gamboa da Costa G; Sennesael J; Cassuto-Viguier E; Ambrosetti D; Rorive S; Pozdzik A; Phillips DH; Stiborova M; Arlt VM
Int J Cancer; 2014 Jul; 135(2):502-7. PubMed ID: 24921086
[TBL] [Abstract][Full Text] [Related]
14. Biomonitoring of aristolactam-DNA adducts in human tissues using ultra-performance liquid chromatography/ion-trap mass spectrometry.
Yun BH; Rosenquist TA; Sidorenko V; Iden CR; Chen CH; Pu YS; Bonala R; Johnson F; Dickman KG; Grollman AP; Turesky RJ
Chem Res Toxicol; 2012 May; 25(5):1119-31. PubMed ID: 22515372
[TBL] [Abstract][Full Text] [Related]
15. Aristolochic acid and the etiology of endemic (Balkan) nephropathy.
Grollman AP; Shibutani S; Moriya M; Miller F; Wu L; Moll U; Suzuki N; Fernandes A; Rosenquist T; Medverec Z; Jakovina K; Brdar B; Slade N; Turesky RJ; Goodenough AK; Rieger R; Vukelić M; Jelaković B
Proc Natl Acad Sci U S A; 2007 Jul; 104(29):12129-34. PubMed ID: 17620607
[TBL] [Abstract][Full Text] [Related]
16. Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid.
Jelaković B; Castells X; Tomić K; Ardin M; Karanović S; Zavadil J
Int J Cancer; 2015 Jun; 136(12):2967-72. PubMed ID: 25403517
[TBL] [Abstract][Full Text] [Related]
17. Molecular markers in upper urothelial carcinoma associated to Balkan endemic nephropathy. Aristolochic acid as the major risk factor of the worldwide disease.
Jankovic Velickovic L; Hattori T; Stefanovic V
ScientificWorldJournal; 2009 Dec; 9():1360-73. PubMed ID: 20024511
[TBL] [Abstract][Full Text] [Related]
18. p53 mutations as fingerprints for aristolochic acid: an environmental carcinogen in endemic (Balkan) nephropathy.
Slade N; Moll UM; Brdar B; Zorić A; Jelaković B
Mutat Res; 2009 Apr; 663(1-2):1-6. PubMed ID: 19428366
[TBL] [Abstract][Full Text] [Related]
19. Urothelial malignant disease and Chinese herbal nephropathy.
Lord GM; Cook T; Arlt VM; Schmeiser HH; Williams G; Pusey CD
Lancet; 2001 Nov; 358(9292):1515-6. PubMed ID: 11705569
[TBL] [Abstract][Full Text] [Related]
20. Mutational Processes in Hepatocellular Carcinoma: The Story of Aristolochic Acid.
Nault JC; Letouzé E
Semin Liver Dis; 2019 Jul; 39(3):334-340. PubMed ID: 31041788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]